LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 27

Search options

  1. Article: Immunotherapies in Late-Stage Development for Patients With Severe SLE and/or Lupus Nephritis.

    Fellner, Chris

    P & T : a peer-reviewed journal for formulary management

    2017  Volume 42, Issue 6, Page(s) 394–397

    Abstract: We review the immunomodulatory agents in development for systemic lupus erythematosus, a relatively uncommon disorder affecting women of childbearing age. ...

    Abstract We review the immunomodulatory agents in development for systemic lupus erythematosus, a relatively uncommon disorder affecting women of childbearing age.
    Language English
    Publishing date 2017-05-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1036637-4
    ISSN 1052-1372
    ISSN 1052-1372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Promising Drugs in Clinical Development To Treat Advanced Colorectal Cancer.

    Fellner, Chris

    P & T : a peer-reviewed journal for formulary management

    2017  Volume 42, Issue 4, Page(s) 262–265

    Abstract: We present immunotherapies, biosimilars, and molecular-targeted agents in late-stage development for patients with advanced colorectal cancer. ...

    Abstract We present immunotherapies, biosimilars, and molecular-targeted agents in late-stage development for patients with advanced colorectal cancer.
    Language English
    Publishing date 2017-04-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1036637-4
    ISSN 1052-1372
    ISSN 1052-1372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: New Schizophrenia Treatments Address Unmet Clinical Needs.

    Fellner, Chris

    P & T : a peer-reviewed journal for formulary management

    2017  Volume 42, Issue 2, Page(s) 130–134

    Abstract: We present several novel drugs in development for enhancing cognition, treating negative symptoms, and providing improved options for treatment-resistant patients. Drug makers aim to enhance safety profiles and increase patient compliance to therapy. ...

    Abstract We present several novel drugs in development for enhancing cognition, treating negative symptoms, and providing improved options for treatment-resistant patients. Drug makers aim to enhance safety profiles and increase patient compliance to therapy.
    Language English
    Publishing date 2017-01-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1036637-4
    ISSN 1052-1372
    ISSN 1052-1372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Multiple Myeloma Market Will Expand With Launch of Monoclonal Antibodies.

    Fellner, Chris

    P & T : a peer-reviewed journal for formulary management

    2016  Volume 41, Issue 1, Page(s) 64–66

    Abstract: Analysts foresee substantial growth in the multiple myeloma market in the next decade, driven mainly by the monoclonal antibodies elotuzumab and daratumumab. ...

    Abstract Analysts foresee substantial growth in the multiple myeloma market in the next decade, driven mainly by the monoclonal antibodies elotuzumab and daratumumab.
    Language English
    Publishing date 2016-01-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1036637-4
    ISSN 1052-1372
    ISSN 1052-1372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Pharmaceutical Approval Update.

    Fellner, Chris

    P & T : a peer-reviewed journal for formulary management

    2016  Volume 41, Issue 1, Page(s) 26–59

    Abstract: Elotuzumab (Empliciti) and ixazomib (Ninlaro) for some multiple myeloma patients; Fluad (influenza vaccine, adjuvanted) for immunization of persons 65 years of age and older; and osimertinib (Tagrisso) for certain non-small-cell lung cancers. ...

    Abstract Elotuzumab (Empliciti) and ixazomib (Ninlaro) for some multiple myeloma patients; Fluad (influenza vaccine, adjuvanted) for immunization of persons 65 years of age and older; and osimertinib (Tagrisso) for certain non-small-cell lung cancers.
    Language English
    Publishing date 2016-01-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1036637-4
    ISSN 1052-1372
    ISSN 1052-1372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market.

    Fellner, Chris

    P & T : a peer-reviewed journal for formulary management

    2016  Volume 41, Issue 8, Page(s) 523–525

    Abstract: Tyrosine kinase inhibitors (TKIs) are leading systemic therapies for the treatment of renal cell carcinoma. However, programmed death-1 inhibitors, promising new agents in development, may surpass TKIs as the standard of care in the future. ...

    Abstract Tyrosine kinase inhibitors (TKIs) are leading systemic therapies for the treatment of renal cell carcinoma. However, programmed death-1 inhibitors, promising new agents in development, may surpass TKIs as the standard of care in the future.
    Language English
    Publishing date 2016-07-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1036637-4
    ISSN 1052-1372
    ISSN 1052-1372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: More Biologic Therapies Expected To Treat Advanced Plaque Psoriasis.

    Fellner, Chris

    P & T : a peer-reviewed journal for formulary management

    2016  Volume 41, Issue 6, Page(s) 388–390

    Abstract: Psoriasis, a disorder that manifests as a variety of chronic inflammatory skin diseases, affects an estimated 7.4 million Americans. We consider five promising biologic agents poised to enter the psoriasis market for advanced disease by 2019. ...

    Abstract Psoriasis, a disorder that manifests as a variety of chronic inflammatory skin diseases, affects an estimated 7.4 million Americans. We consider five promising biologic agents poised to enter the psoriasis market for advanced disease by 2019.
    Language English
    Publishing date 2016-01-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1036637-4
    ISSN 1052-1372
    ISSN 1052-1372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Zika in America: The Year in Review.

    Fellner, Chris

    P & T : a peer-reviewed journal for formulary management

    2016  Volume 41, Issue 12, Page(s) 778–791

    Abstract: Short on funds and with no therapeutics or vaccines in sight, U.S. health officials are scrambling to prepare for a protracted fight with Zika virus and the mosquitoes that carry it. In this article, the author focuses on the arrival of Zika in the U.S. ...

    Abstract Short on funds and with no therapeutics or vaccines in sight, U.S. health officials are scrambling to prepare for a protracted fight with Zika virus and the mosquitoes that carry it. In this article, the author focuses on the arrival of Zika in the U.S.
    Language English
    Publishing date 2016-12-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1036637-4
    ISSN 1052-1372
    ISSN 1052-1372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Novel Treatments Target Type-2 Diabetes.

    Fellner, Chris

    P & T : a peer-reviewed journal for formulary management

    2016  Volume 41, Issue 10, Page(s) 650–653

    Abstract: Patients with type-2 diabetes can control their blood glucose levels through diet and exercise, by losing excess weight, and by taking medications, such as first-line metformin. We examine several promising drugs in the type-2 diabetes pipeline. ...

    Abstract Patients with type-2 diabetes can control their blood glucose levels through diet and exercise, by losing excess weight, and by taking medications, such as first-line metformin. We examine several promising drugs in the type-2 diabetes pipeline.
    Language English
    Publishing date 2016-10-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1036637-4
    ISSN 1052-1372
    ISSN 1052-1372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Pharmaceutical Approval Update.

    Fellner, Chris

    P & T : a peer-reviewed journal for formulary management

    2015  Volume 41, Issue 3, Page(s) 162–163

    Abstract: Elbasvir/grazoprevir (Zepatier) for chronic hepatitis C virus; sumatriptin nasal powder (Onzetra Xsail) for migraine; eribulin mesylate (Halaven), now for liposarcoma; and extended-release amphetamine (Adzenys XR-ODT) for ADHD. ...

    Abstract Elbasvir/grazoprevir (Zepatier) for chronic hepatitis C virus; sumatriptin nasal powder (Onzetra Xsail) for migraine; eribulin mesylate (Halaven), now for liposarcoma; and extended-release amphetamine (Adzenys XR-ODT) for ADHD.
    Language English
    Publishing date 2015-07-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1036637-4
    ISSN 1052-1372
    ISSN 1052-1372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top